Early study success for targeted radiation:
This article was originally published in Clinica
NeoRx has reported that its Pretarget technology cured established human lung, colon and breast cancers implanted into mice in a preclinical study. Complete disappearance of tumours and no regrowth after one year occurred in 100% (10/10) of lung cancers, 100% (10/10) of colon cancers and 80% (8/10) of breast cancers. With Pretarget, a targeting antibody and radiation are injected separately and at different times and join at tumour sites where the antibody has pre-localised, said the Seattle, Washington-based company. The study was published in the Proceedings of the National Academy of Sciences (February 15).